Chris Beddard[email protected]InfectiousThe next phase of diagnostic testing is here and ready to scaleIt is time to provide more advanced insight on patient health and more informed treatment options for clinicians in the U.S. Few diagnostic tools and systems on the market today are available to scale and even fewer provide extended genotyping capabilities. This gap can hamper patient care by masking or misdiagnosing illnesses and strains, potentially leading physicians to advise treatment plans that lack precision or that may be unnecessary.November 10, 2021Page 1 of 1Top StoriesCollaborationVertex to pay $25M upfront to scale cell manufacturing technologyAs part of the deal, Vertex was also willing to pay up to $215 million in milestones achieved in connection with the development of a scaled-up process for fully differentiated islet cells.LawsuitU.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuitPoint-of-Care TestingScout secures CARB-X grant to advance diagnostic test developmentSequencingMission Bio launches new features for Tapestri platformSponsor ContentVisit our Molecular Diagnostics Community